Nanomedicine-mediated induction of immunogenic cell death and prevention of PD-L1 overexpression for enhanced hepatocellular carcinoma therapy
Abstract Background The present study aims to develop a nanoparticle encapsulating doxorubicin (DOX) and programmed death-ligand 1 (PD-L1) siRNA and evaluate its anti-tumor effects on hepatoma carcinoma (HCC). Methods Nanoparticle encapsulating DOX and PD-L1 siRNA (NPDOX/siPD-L1) was characterized b...
Main Authors: | Hanzhang Zhu, Weijiang Zhou, Yafeng Wan, Ke Ge, Jun Lu, Changku Jia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Cancer Nanotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12645-020-00072-6 |
Similar Items
-
Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01) -
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
by: María Merino, et al.
Published: (2021-04-01) -
Doxorubicin‐loaded nanoparticle coated with endothelial cells‐derived exosomes for immunogenic chemotherapy of glioblastoma
by: Chao Zhang, et al.
Published: (2021-09-01) -
Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
by: Ken Maes, et al.
Published: (2019-07-01) -
Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
by: Zhenqing Wang, et al.
Published: (2021-08-01)